A TWO-YEAR EVALUATION OF CHLORPROMAZINE IN CLINICAL RESEARCH AND PRACTICE
Abstract
In conclusion, we believe that chlorpromazine has established itself as a useful therapeutic tool in the treatment of mental illness. It is a relatively safe drug, and although the side-effects are many, serious or permanent sequelae are almost unknown. In regard to its therapeutic effect in our case material much is left to be desired. Its range of application appears to be narrow, being most effective in agitated, hyperactive, and overtly anxious patients, with much more limited value in depression, or with obsessive patients manifesting little or no increase in motor function. It is palliative rather than curative. It can intensify anxiety and precipitate depression and psychotic symptoms as well as alleviate them. Its major advantage lies in its tranquilizing action without accompanying marked drowsiness or confusion. Its value as an adjunct to psychotherapy is still to be evaluated.
Chlorpromazine has been a major force in firmly launching us into the era of psychopharmacology. We are still suffering, however, from all the uncertainties and hesitation of a pioneer venture. This should not deter us from continued investigation and progress.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
